February 25, 2025 10:34 AM EST
Health Tech

Is the GLP-1 com­pound­ing boom over? Not ex­act­ly

Shelby Livingston

Senior health tech reporter

We’re about to see what hap­pens when com­pound­ing goes from fill­ing a gap left by a sup­ply short­age, to more di­rect­ly com­pet­ing with phar­ma. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

On the heels of staff cuts, CRISPR Ther­a­peu­tics COO de­parts; Changes ga­lore at Bi­cy­cle

Mer­ck KGaA pays Ab­bisko $85M for full com­mer­cial rights to be­nign tu­mor drug

Be­fore Alu­mis went pub­lic via IPO, it tried do­ing a re­verse merg­er with Ace­lyrin

FDA’s pol­i­cy, com­mu­ni­ca­tions staff like­ly to be among agency’s 3,500 staff cuts

With tar­iffs on the way, gener­ic drug­mak­ing woes could hin­der Trump’s reshoring plan 

A service from the Financial Times